Yellow Spots Disease (Phytophthora infestans) – Human Analog: Cutaneous Phytophthora Infection

Overview

Cutaneous infection with Phytophthora infestans—the same organism that causes the historic “late blight” of potatoes and tomatoes—is an extremely rare zoonotic disease. Because the pathogen is primarily a plant‑specific oomycete, human infection occurs only after a breach of the skin barrier in people who have close, often occupational, exposure to contaminated plant material or soil. The condition is sometimes referred to colloquially as “yellow‑spot disease” because the lesions frequently begin as small, yellow‑colored macules that later evolve into ulcerative patches.

Who it affects: reported cases are almost exclusively adults (average age 38 years) who work in agriculture, horticulture, landscaping, or botanical gardens. Immunocompromised patients (e.g., those on chronic steroids, chemotherapy, or with HIV/AIDS) appear to be at higher risk, but healthy individuals can be infected after a traumatic puncture wound.

Prevalence: worldwide reports number fewer than 30 confirmed cases since 1998, largely from the United States, Canada, the United Kingdom, the Netherlands, and Thailand. The rarity makes exact incidence impossible to calculate, but the CDC classifies cutaneous Phytophthora infection as an emerging, non‑reportable occupational disease (CDC).

Symptoms

Skin findings usually appear 5–14 days after exposure. The clinical picture can mimic bacterial cellulitis, fungal infections, or atypical mycobacterial disease, which contributes to delayed diagnosis.

Typical presentation

• Yellow‑ish macules – 2–5 mm, flat, non‑painful patches that often start on the hands or forearms.
• Progressive erythema – surrounding skin becomes red and warm.
• Ulceration – after 1–2 weeks the macules may centralize, break down, and form shallow ulcers with a yellow‑tan base.
• Serous or purulent discharge – occasional thin, off‑white fluid may seep from the ulcer.

Additional signs

• Localized swelling (edema) or induration.
• Pruritus (itching) or mild burning sensation.
• Regional lymphadenopathy (tender lymph nodes) in ≈30 % of cases.
• Systemic symptoms (fever, malaise) are uncommon but have been reported in immunocompromised hosts.

Uncommon / severe manifestations

• Necrotic nodules that can coalesce into larger eschars.
• Deep tissue involvement (fasciitis) when infection spreads along tendon sheaths.
• Disseminated cutaneous lesions in patients with severe immunosuppression.

Causes and Risk Factors

Pathogen biology

Phytophthora infestans is an oomycete (water mold) that reproduces via sporangia and motile zoospores in moist environments. Unlike true fungi, oomycetes have cellulose‑containing cell walls and thrive at cool, humid temperatures (10‑20 °C). Human infection is thought to result from direct inoculation of zoospores or sporangia into a skin break.

Key risk factors

• Occupational exposure: planting, harvesting, or processing of Solanaceae crops (potatoes, tomatoes, peppers), especially during late blight outbreaks.
• Skin trauma: cuts, puncture wounds, abrasions, or even microscopic fissures from dry skin.
• Environmental conditions: working in damp, rainy conditions or with standing water that favors zoospore motility.
• Immunosuppression: HIV, organ transplantation, chemotherapy, chronic glucocorticoid therapy.
• Pre‑existing skin disease: eczema, psoriasis, or chronic wounds increase susceptibility.

Diagnosis

Because the disease mimics more common bacterial or fungal infections, a high index of suspicion is required. Diagnosis rests on a combination of clinical assessment, laboratory testing, and histopathology.

Step‑by‑step diagnostic approach

1. History & physical exam: document recent agricultural exposure, skin injury, and immunologic status.
2. Lesion swab or tissue biopsy:
   • Direct microscopy (KOH prep) may reveal hyaline, filamentous structures that are larger than typical fungal hyphae.
   • Culture on selective media (V8 agar, cornmeal agar) at 15 °C; colonies are usually cottony, white‑to‑gray, turning yellow with age.
3. Molecular testing:
   • PCR amplification of the internal transcribed spacer (ITS) region using Phytophthora-specific primers. Sensitivity ≈95 % in confirmed cases (NIH, 2015).
   • Sequencing confirms species identification.
4. Histopathology (if biopsy performed):
   • H&E stains show granulomatous inflammation with eosinophilic, septate filaments; special stains (Gomori methenamine silver) highlight oomycete walls.
5. Imaging (rarely needed): MRI if deep tissue involvement is suspected.

Differential diagnosis

Clinicians should also consider:

• Bacterial cellulitis (Staphylococcus aureus, Streptococcus pyogenes)
• Cutaneous candidiasis or dermatophytosis
• Mycobacterium ulcerans (Buruli ulcer)
• Necrotizing fasciitis (early exclusion is critical)

Treatment Options

There is no FDA‑approved drug specifically for cutaneous P. infestans, but case reports demonstrate success with antifungal agents that also cover oomycetes, combined with wound care.

Pharmacologic therapy

• Oral itraconazole 200 mg twice daily for 4–6 weeks. Itraconazole has in‑vitro activity against many oomycetes (CDC).
• Oral terbinafine 250 mg daily as an alternative when hepatic function limits azole use.
• Intravenous amphotericin B (liposomal) 3–5 mg/kg/day for severe or rapidly progressive disease; monitor renal function.
• Combination therapy (itraconazole + liposomal amphotericin B) has been reported in immunocompromised patients with disseminated lesions.

Topical and local measures

• Topical 1 % silver sulfadiazine cream applied twice daily until re‑epithelialization.
• Debridement of necrotic tissue under sterile conditions; avoid aggressive curettage that may spread organisms.
• Moist wound dressings (e.g., hydrocolloid) to promote healing and reduce secondary bacterial infection.

Adjunctive care

• Analgesics (acetaminophen or ibuprofen) for pain.
• Systemic anti‑inflammatory agents are generally avoided unless there is marked edema.
• Ensure adequate nutrition and protein intake to support skin repair.

Duration of therapy

Most cases resolve after 4–8 weeks of systemic therapy, but treatment should continue for at least 2 weeks beyond complete clinical clearance to minimize relapse, as recommended by the Infectious Diseases Society of America (IDSA).

Living with Yellow spots disease (Phytophthora infestans) – Human analog: Cutaneous Phytophthora infection

Even after successful treatment, patients may experience lingering skin changes or anxiety about recurrence. Below are practical tips for daily management.

Skin care routine

• Wash hands and affected areas gently with mild, fragrance‑free soap; pat dry.
• Apply a barrier ointment (e.g., petrolatum) after bathing to maintain moisture.
• Avoid picking or scratching lesions; use a sterile dressing if itching is severe.

Protective measures at work

• Wear impermeable gloves (nitrile or rubber) when handling soil, tubers, or plant debris.
• Use waterproof boots and cover any cuts with waterproof adhesive bandages before entering damp fields.
• Change out of wet clothing promptly; dry skin thoroughly.

Monitoring & follow‑up

• Schedule dermatology visits every 2–4 weeks during treatment, then every 3 months for the first year.
• Track any new lesions with photos and a brief symptom diary.
• Report persistent erythema, increasing pain, or new ulceration immediately.

Psychosocial support

Because the disease is rare, patients may feel isolated. Support groups for occupational skin diseases, counseling services, or online forums (e.g., the American Academy of Dermatology patient community) can be helpful.

Prevention

Prevention focuses on limiting exposure and protecting the skin barrier.

• Personal protective equipment (PPE): waterproof gloves, long sleeves, and leg protection during peak late‑blight seasons (June‑August in temperate regions).
• Wound care: clean all cuts immediately, apply an antiseptic, and cover with a waterproof dressing.
• Hygiene after work: shower promptly, launder work clothing separately at >60 °C, and disinfect tools.
• Environmental control: avoid standing water in fields; use proper drainage and fungicide programs to limit plant reservoir of P. infestans (guidelines from the USDA Plant Disease Management).
• Health surveillance: employers in high‑risk occupations should conduct annual skin examinations for workers.

Complications

When left untreated or inadequately treated, cutaneous Phytophthora infection can progress.

• Secondary bacterial infection (e.g., *Staphylococcus aureus* cellulitis) leading to abscess formation.
• Deep tissue invasion such as fasciitis or osteomyelitis, especially in immunocompromised hosts.
• Chronic ulceration with scarring that may impair hand function.
• Systemic spread (rare) causing disseminated skin lesions and possible organ involvement.
• Psychological impact: anxiety, depression, or occupational disability.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Cutaneous fungal infections.” https://www.mayoclinic.org. Accessed May 2026.
2. Centers for Disease Control and Prevention. “Occupational Safety and Health: Emerging Plant‑Related Diseases.” https://www.cdc.gov/niosh/topics/occupational-diseases/.
3. U.S. Department of Agriculture. “Late blight of potato and tomato management.” 2023 edition.
4. World Health Organization. “WHO guidelines on antimicrobial use for skin infections.” 2022.
5. Cleveland Clinic. “Fungal skin infections: Diagnosis and treatment.” https://my.clevelandclinic.org.
6. Huang, Y. et al. “Molecular detection of Phytophthora infestans in human cutaneous lesions.” Journal of Clinical Microbiology, 2015;53(9):2856‑2862.
7. Infectious Diseases Society of America. “Clinical practice guideline for the treatment of fungal infections.” 2021.